Attention Deficit Hyperactivity Disorder (ADHD). Disturbance of activity and attention
Conditions
Interventions
Intervention 1: Intervention group1: Methyl phenidate (Ritlin: 1mg/kg) combined with Cyproheptadin (Razi: 12 mg/day- 4mg before each meal). Intervention 2: Intervention group2: Methyl phenidate (Ritli
Treatment - Drugs
Intervention group1: Methyl phenidate (Ritlin: 1mg/kg) combined with Cyproheptadin (Razi: 12 mg/day- 4mg before each meal)
Intervention group2: Methyl phenidate (Ritlin: 1mg/kg) combined with Folic acid (Alhavi: 5 mg/day)
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
7 Years to 12 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age range of 7-12; ADHD combined form; Clinical need to treat with Methylphenidate; parental consent and child ascent Exclusion criteria: any confounding co-morbiditis; any drug supplements or narcotics consumption; Children with history of major prenatal complications such as prematurity, low birth weight (reported by parents), any past or present psychosis, comorbid tourette syndrome, celiac, phenylketonuria, autism, or other persistent developmental disorders
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Attention deficiency score and Hyperactivity score. Timepoint: 0-2-4-8 weeks. Method of measurement: ADHD rating scale for children (complited by parents).;Appetite score. Timepoint: 0-2-4-8 weeks. Method of measurement: Standard appetite questionnaire for chilldren.;Sleep disorders score. Timepoint: 0-2-4-8 weeks. Method of measurement: Sleep disorders scale for chilldren (SDSC). | — |
Secondary
| Measure | Time frame |
|---|---|
| Stimulants side effects. Timepoint: week 8. Method of measurement: Stimulants side effects questionnare. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Ali Mostafavi
Tehran University of Medical Sciences
Outcome results
None listed